ReviewMicroorganisms2022
Updated Review on the Mechanisms of Pathogenicity in
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Expanding the scope of Mycobacterium abscessus reference strains to improve pulmonary disease modeling.Disease models & mechanisms · 2026Article
- Article
- Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.American journal of respiratory and critical care medicine · 2026Article
- Defining the Mechanism of Action and Resistance of NewACS chemical biology · 2026Article
- Challenges in the Diagnosis and Treatment of Mycobacterium abscessus Infections.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- Mycobacterium abscessus lumbar osteomyelitis: A rare and challenging case with review of literature.IDCases · 2026Article
- Expanding the scope ofbioRxiv : the preprint server for biology · 2025Article
- ATG7 in innate immune cells is required for host defense against nontuberculous mycobacterial pulmonary infections.Nature communications · 2025Article
- Evaluation of the In Vitro Activity of Bedaquiline, Delamanid, and Clofazimine AgainstPathogens (Basel, Switzerland) · 2025Article
- Clinical Trials involvingThe Ulster medical journal · 2025Article
- Biofilm Formation in Mycobacterial Genus; Mechanism of Biofilm Formation and Anti-mycobacterial Biofilm Agents.Current pharmaceutical biotechnology · 2025Review
- Article
- Trehalose polyphleates participate inmBio · 2024Article
- Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery.npj antimicrobials and resistance · 2024Review
- Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.The Journal of antimicrobial chemotherapy · 2024Review
- Evolution toward extremely high imipenem resistance inAntimicrobial agents and chemotherapy · 2024Article
- Targeting Intracellular Bacteria with Dual Drug-loaded Lactoferrin Nanoparticles.ACS infectious diseases · 2024Article
- Evolution towards extremely high β-lactam resistance inbioRxiv : the preprint server for biology · 2024Article
- Microevolution, reinfection and highly complex genomic diversity in patients with sequential isolates of Mycobacterium abscessus.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.